Molecular Templates Inc

Molecular Templates — Threshold Pharmaceuticals — Merger or Acquisition (March 2017)

34 slides from Molecular Templates's merger presentation, Mar 29, 2017

  1. Slide 1: Molecular Templates / Threshold Pharmaceuticals

    APRIL 2017 MOLECULAR TEMPLATES / THRESHOLD PHARMACEUTICALS Filed by Threshold Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a - 12 under the Securities Exchange Act of 1934 Subject Company: Threshold Pharmaceuticals, Inc. Commission F

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements 2 Except for statements of historical fact, the statements in this presentation are forward - looking statements, including statemen ts regarding the proposed merger with Threshold Pharmaceuticals; the future development of Molecular Templates proprietary Engineered Toxi

  3. Slide 3: Important Information for Investors and Stockholders

    Important Information for Investors and Stockholders 3 Important Information for Investors and Stockholders This communication may be deemed to be solicitation material in respect of the proposed transaction between Threshold Pharmac eut icals, Inc. (Threshold) and Molecular Templates, Inc. (Molecul

  4. Slide 4: Threshold and Molecular Templates: Advantages of New Company

    Threshold and Molecular Templates : Advantages of New Company Development of Molecular Templates proprietary Engineered Toxin Body (ETB) technology o Lead compound MT - 3724 initiating phase II program in NHL in 2017 o Development of multiple pipeline compounds and large pharma collaborations expect

  5. Slide 5: Evofosfamide: Combination development with checkpoint inhibitor Ipilimumab

    Evofosfamide Combination development with checkpoint inhibitor Ipilimumab

  6. Slide 6: Evofosfamide: continued development in new company

    Evofosfamide : continued development in new company Evofosfamide did not meet primary endpoint in two phase III trials (MAESTRO and TH - CR - 406/ SARCO21) o The MAESTRO study in pancreatic adenocarcinoma did not demonstrate a statistically significant improvement in overall survival (OS) for evofos

  7. Slide 7: The ETB scaffold

    The ETB scaffold Proprietary platform with novel mechanism leveraging powerful biology

  8. Slide 8: Engineered Toxin Bodies platform overview

    Engineered Toxin Bodies (ETBs) are comprised of an antibody fragment binding domain genetically fused to a proprietarily engineered Shiga - Like Toxin A - Subunit (SLT - A) Molecular Templates I Engineered Toxin Body (ETB) platform Platform Capabilities Forced Receptor Internalization (1 st generati

  9. Slide 9: Shiga-Like Toxin A has well defined biological properties

    Shiga - Like Toxin A (SLT - A) has well defined biological properties Unique SLT - A Biological Properties o Can force receptor internalization o Self - routes to the cytosol o Irreversibly and enzymatically inactivates ribosomes activity to destroy target cells • Novel intracellular mechanism of ce

  10. Slide 10: SLT-A based engineered immunotoxins are potent

    SLT - A based engineered immunotoxins are potent SLT - A Subunit o Forces cell entry o Self - routes inside in the cell o Enzymatic and irreversible ribosome de - purination SLT - B Subunit o Binds CD77 (Gb3) – a non - internalizing glycosphingolipid Modified SLT - A o Engineered from SLT - A o Reta

  11. Slide 11: MTEM's proprietary ETB platform is differentiated

    MTEM’s proprietary ETB platform is differentiated ANTIBODY ADC CAR - T CD3 BISPECIFIC ETB Mechanism of Action (MOA) ADCC/CDC Chemotherapy T - cell engagement T - cell engagement Novel MOA (ribosomal destruction) Target Does not n eed to internalize Must internalize Does not need to internalize Does

  12. Slide 12: MT-3724 1st generation scaffold

    MT - 3724 1 st generation scaffold

  13. Slide 13: MT-3724 is a novel approach to target CD20

    MT - 3724, a 1 st generation ETB, is a novel approach to target CD20 Rituximab o Binds CD20 (does not internalize) o Destroys tumor cells by ADCC/CDC Bexxar & Zevalin o Bind CD20 (do not internalize) o Destroys tumor cells by localized radiation MT - 3724 o 1 st generation ETB o Binds CD20; forces i

  14. Slide 14: MT-3724 preclinical in vitro and in vivo activity

    MT - 3724 has potent in vitro and in vivo activity in pre - clinical models In vitro activity against CD20+ cells Cell Line CD20 CD 50 ( nM ) Raji + 0.36 Daudi + 1.49 Jeno - 1 + 1.53 ST - 486 + 1.70 NHL Rituxan Fail A + 0.1 NHL Rituxan Fail B + 5.0 Jurkat Neg. 1412 BC - 1 Neg. 2051 Untreated Mice MT

  15. Slide 15: Overview of MT-3724 phase I trial in NHL patients

    Overview of MT - 3724 phase I trial in NHL patients Baseline Characteristics 15 Monotherapy 3+3 Dose - Escalation Study in NHL o Failed chemo and CD20 antibody therapy, all subtypes o 1st cycle: 2 weeks on (M - W - F), 2 weeks off of dosing o Subsequent cycles are 2 weeks on (M - W - F), 1 week off

  16. Slide 16: MT-3724 demonstrated promising results in DLBCL patients

    MT - 3724 demonstrated promsing results in DLBCL patients Efficacy • Robust B - cell depletion • Multiple patients had significant clinical responses • Responses seen in patients who had failed multiple prior regimens • No meaningful anti - drug antibodies Safety/tolerability • Very well tolerated •

  17. Slide 17: MT-3724 development in DLBCL; potential pivotal study start in 1Q18

    MT - 3724 development in DLBCL; potential pivotal study start in 1Q18 17 Refractory DLBCL Patient Population Treatment Regimen Endpoint PIb expansion N=9 rel /ref DLBCL with no serum Rituxan MT - 3724 monotherapy Overall Response Rate PII Pivotal N=150 rel /ref DLBCL with no serum Rituxan MT - 3724

  18. Slide 18: MT-3724 is commercially attractive in DLBCL

    MT - 3724 is commerically attractive in DLBCL Extremely high unmet medical need in salvage DLBCL o Overall survival with salvage therapy and SCT is ~ 3 years o Survival for patients ineligible for stem cell transplant or stem cell transplant relapsers is <1 yr Response rate of ~30% would likely be a

  19. Slide 19: 2nd gen. ETB scaffold

    2 nd gen. ETB scaffold De - immunized and higher potency

  20. Slide 20: 2nd generation ETB scaffold overview

    2 nd generation ETB scaffold overview 1 st generation • High Potency A VL VH HIGH POTENCY A VL VH REDUCED IMMUNOGENICITY ANTIGEN SEEDING A VL VH • Improved engineering of molecule (fit between SLTA and scFv) • Engineered scaffold for reduced innate (safety) and adaptive (potency) immunity Higher Pot

  21. Slide 21: MT-4019: 2nd generation ETB targeting CD38

    MT - 4019: 2 nd generation ETB targeting CD38 entering clinic in 2018 21 MT - 4019 CD38 is an ectoenzyme central to disease o Daratumumab has unprecedented single agent activity Daratumumab failures retain CD38 expression o Patients who progress on Daratumumab therapy show increase in CD55/CD59 leve

  22. Slide 22: MT-4019 has picomolar activity and reduced ADA response

    MT - 4019 has picomolar activity and reduced ADA response 22 Cell Line Type CD38 Expression (MFI) CD55/CD59 Expression CD 50 H929 Multiple myeloma 55,000 >50,000 16pM Daudi B - lymphoblast 166,000 <20,000 58pM ST486 B - lymphoblast 129,000 <20,000 41pM MOLP - 8 Multiple myeloma 146,000 >50,000 228pM

  23. Slide 23: 2nd generation ETBs targeting solid tumors enter clinic in 2018

    2 nd generation ETBs targeting solid tumors enter clinic in 2018 23 HER2 o HER2 receptor persists after failure of other modalities ( antibody , TKI, ADC) o Lead ETB compound is non - competitive with trastuzumab / trastuzumab - DM1 o Novel mechanism of action • Up to 50 - fold more potent tan Kadcy

  24. Slide 24: 3rd gen. ETB scaffold: Antigen Seeding

    3 rd gen. ETB scaffold Antigen Seeding

  25. Slide 25: 3rd generation ETB scaffold adds immuno-oncology activity

    3 rd generation ETB scaffold adds immuno - oncology activity to platform A VL VH HIGH POTENCY A VL VH REDUCED IMMUNOGENICITY ANTIGEN SEEDING A VL VH “Antigen Seeding” capability represents the next generation immuno - oncology approach Higher Potency and De - Immunized Next - Gen Immune Oncology 25

  26. Slide 26: SLT-A scaffold can deliver payload of MHC-I antigens

    SLT - A scaffold can deliver payload of MHC - I antigens for cell surface presentation 3 rd generation ETB scaffold incorporates immuno - oncology activity Nucleus Golgi Endoplasmic Reticulum Endosome Cytosol Cleaved Antigen ETB with Class I Viral Antigen Target Cytotoxic T - Cells TCR MHC - I Antig

  27. Slide 27: CMV-specific CD8+ T-cells and antigen seeding on PD-L1 construct

    CMV - specific CD8+ T - cells undergo unique progressive expansion (memory inflation) and accumulate in periphery o Up to 20% of T - cells in elderly hosts are specific to pp65 CMV - specific CD8+ T - cells may be resistant to exhaustion (decreased PD - 1, CD160, CD244 expression) o CMV - specific C

  28. Slide 28: CMC: Off-the-shelf, scalable ETB manufacturing

    CMC Off - the - shelf, scalable ETB manufacturing

  29. Slide 29: ETB GMP manufacturing is efficient and scalable

    ETB GMP manufacturing is efficient and scalable GMP Expression System & Format – Engineered BL21 derived E. Coli – Optimized for soluble expression – 24 hour fermentation process – In - house PD to scale from 5L to 300L reactor – 7x GMP campaigns at 300L scale with MT - 3724 – Two - step affinity pu

  30. Slide 30: Milestones

    Milestones Next 18 months

  31. Slide 31: Significant milestones over next months

    31 Significant milestones over next 18 months Mar ‘17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 MT - 3724 (CD20) P2 Chemo Intolerant Induction/Consolidation DLBCL P2 Pivotal (Interim) Ref/ Rel DLBCL Stop Gap P2 GMP MFG Pipeline IND/GMP Phase 1 MTD IND/GMP P2 Double Hit Protein Expressing Induction/Con

  32. Slide 32: Summary

    Summary Publicly traded oncology company

  33. Slide 33: MTEM is a clinical stage oncology company with a distinctive platform

    MTEM is a clinical stage oncology company with a distinctive platform Lead compound (MT - 3724) has novel mechanism of action, good safety, and monotherapy activity o Proof - of - concept for internalization of non - internalizing receptors (CD20) o Novel MOA is active in patients refractory to chem

  34. Slide 34: Evofosfamide: continued development in new company

    Evofosfamide : continued development in new company Evofosfamide did not meet primary endpoint in two phase III trials (MAESTRO and TH - CR - 406/ SARCO21) o The MAESTRO study in pancreatic adenocarcinoma did not demonstrate a statistically significant improvement in overall survival (OS) for evofos

Threshold Pharmaceuticals — Merger or Acquisition (March 2017) on 6ix